These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 26866506)

  • 1. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
    Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
    Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
    Källmark H; Einarsson JT; Nilsson JÅ; Olofsson T; Saxne T; Geborek P; C Kapetanovic M
    Arthritis Rheumatol; 2021 Jul; 73(7):1135-1144. PubMed ID: 33682353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.
    Bergstra SA; Allaart CF; Ramiro S; Chopra A; Govind N; Silva C; Murphy EA; Landewé RBM
    J Rheumatol; 2018 Oct; 45(10):1361-1366. PubMed ID: 29907672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
    Kim SC; Yelin E; Tonner C; Solomon DH
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1529-33. PubMed ID: 23463543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
    Calgüneri M; Pay S; Calişkaner Z; Apraş S; Kiraz S; Ertenli I; Cobankara V
    Clin Exp Rheumatol; 1999; 17(6):699-704. PubMed ID: 10609068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.